Evidence map›Paper›PMID 37225278›Full record

ArticleBMJ open2023

Accelerating clinical development of a live attenuated vaccine against

Naina McCann, Katherine Emary, Nisha Singh, Florence Mclean, Susana Camara, Elizabeth Jones, Young Chan Kim, Xinxue Liu, Melanie Greenland, Kerry Conlin and 7 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Combatting extensively drug-resistantPathogens and global health
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 3 countries.

Naina McCannDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK naina.mccann@paediatrics.ox.ac.uk.ORCID 0000-0001-5864-1175
Katherine EmaryDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
Nisha SinghDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
Florence McleanDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
Susana CamaraDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
Elizabeth JonesDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
Young Chan KimDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
Xinxue LiuDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.ORCID 0000-0003-1107-0365
Melanie GreenlandDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
Kerry ConlinDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
Jennifer HillDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
Marije VerheulDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
Hannah RobinsonDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
Brian AngusDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.ORCID 0000-0003-3598-7784
Maheshi N RamasamyDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
Myron M LevineCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Andrew J PollardDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.ORCID 0000-0001-7361-719X
University of Oxford · GBUniversity of Maryland, Baltimore · US

Funding

Medical Research Council MR/RO25347/1
6 · The paper itself

Abstract

introductionThis is the first efficacy study of an oral live attenuated vaccine against METHODS AND ANALYSIS: This is an observer-blind, randomised, placebo-controlled trial phase I/II of the oral live-attenuated vaccine against ETHICS AND DISSEMINATION: Ethical approval for this study has been obtained from the Berkshire Medical Research Ethics Committee (REC ref 21/SC/0330). The results will be disseminated via publication in a peer-reviewed journal and presentation at international conferences. TRIAL REGISTRATION NUMBER: ISRCTN15485902.

Indexed as

Cardiovascular DiseasesSalmonella paratyphi AAdultClinical Trials, Phase I as TopicHealthy VolunteersHumansRandomized Controlled Trials as TopicVaccines, AttenuatedVolunteersVaccines, AttenuatedClinical trialsINFECTIOUS DISEASESMICROBIOLOGY

Identifiers

PMID37225278
PMCPMC10230971
OpenAlexW4378173048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.